Skip to main content
Journal cover image

Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke.

Publication ,  Journal Article
Chang, K-W; Xian, Y; Zhao, X; Mi, X; Matsouaka, R; Schwamm, LH; Shah, S; Lytle, BL; Smith, EE; Bhatt, DL; Fonarow, GC; Hsu, JC
Published in: Int J Cardiol
December 15, 2020

BACKGROUND: To determine association of discharge antiplatelet therapy prescription with 1-year outcomes among patients with AF admitted with acute ischemic stroke and discharged without oral anticoagulation. METHODS: In a retrospective cohort study from the Get With The Guidelines-Stroke registry, we identified all Medicare fee-for-service beneficiaries 65 years or older with AF or atrial flutter admitted with acute ischemic stroke and discharged without oral anticoagulation from April 2003 through December 2014, and we determined association of discharge antiplatelet therapy prescription with 1-year outcomes using Medicare claims data. Primary outcomes were 1-year mortality and composite endpoint of major adverse cardiovascular/neurologic/bleeding events (MACNBE). RESULTS: Of 64,228 subjects (median [interquartile range] age, 84 [78-89] years; 62.5% female), 54,621 (85.0%) were discharged with antiplatelet therapy, and 9607 (15.0%) were discharged with no antithrombotic therapy. The unadjusted rates of 1-year mortality were lower among patients receiving antiplatelet therapy (37.3%) than among those receiving no antithrombotic therapy (48.1%); unadjusted rates of MACNBE were lower for those receiving antiplatelet therapy (45.5%) compared with those receiving no antithrombotic therapy (55.2%). After adjusting for potential confounders, antiplatelet therapy prescription was associated with reduced 1-year mortality (adjusted hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.62-0.66, P < .001) and MACNBE (adjusted HR 0.69, 95% CI 0.67-0.71, P < .001). CONCLUSIONS: Among Medicare beneficiaries with AF admitted for acute ischemic stroke but not discharged on oral anticoagulant therapy, antiplatelet therapy, compared with no antithrombotic therapy, was associated with reduced 1-year mortality and MACNBE.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Cardiol

DOI

EISSN

1874-1754

Publication Date

December 15, 2020

Volume

321

Start / End Page

88 / 94

Location

Netherlands

Related Subject Headings

  • United States
  • Treatment Outcome
  • Stroke
  • Risk Factors
  • Retrospective Studies
  • Platelet Aggregation Inhibitors
  • Medicare
  • Male
  • Humans
  • Fibrinolytic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chang, K.-W., Xian, Y., Zhao, X., Mi, X., Matsouaka, R., Schwamm, L. H., … Hsu, J. C. (2020). Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. Int J Cardiol, 321, 88–94. https://doi.org/10.1016/j.ijcard.2020.08.011
Chang, Kay-Won, Ying Xian, Xin Zhao, Xiaojuan Mi, Roland Matsouaka, Lee H. Schwamm, Shreyansh Shah, et al. “Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke.Int J Cardiol 321 (December 15, 2020): 88–94. https://doi.org/10.1016/j.ijcard.2020.08.011.
Chang K-W, Xian Y, Zhao X, Mi X, Matsouaka R, Schwamm LH, et al. Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. Int J Cardiol. 2020 Dec 15;321:88–94.
Chang, Kay-Won, et al. “Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke.Int J Cardiol, vol. 321, Dec. 2020, pp. 88–94. Pubmed, doi:10.1016/j.ijcard.2020.08.011.
Chang K-W, Xian Y, Zhao X, Mi X, Matsouaka R, Schwamm LH, Shah S, Lytle BL, Smith EE, Bhatt DL, Fonarow GC, Hsu JC. Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. Int J Cardiol. 2020 Dec 15;321:88–94.
Journal cover image

Published In

Int J Cardiol

DOI

EISSN

1874-1754

Publication Date

December 15, 2020

Volume

321

Start / End Page

88 / 94

Location

Netherlands

Related Subject Headings

  • United States
  • Treatment Outcome
  • Stroke
  • Risk Factors
  • Retrospective Studies
  • Platelet Aggregation Inhibitors
  • Medicare
  • Male
  • Humans
  • Fibrinolytic Agents